Novo Nordisk has also cited indirect comparison data suggesting that fewer patients discontinued oral semaglutide due to side effects compared with orforglipron, though the companies and independent commentators note the significant methodological limitations of such comparisons in the absence of a head-to-head obesity trial
This mechanism differs fundamentally from stimulant-based diet pills that increase heart rate or metabolism
Route studied In the human trials it was given as a once-weekly injection under the skin, under clinician supervision
The condition can cause sudden, painless vision loss and, in some cases, the damage may be permanent
Thorn, S
le Roux CW, Bueter M, Theis N, Werling M, Ashrafian H, Lwenstein C, et al